Associations between clinical manifestations and SLE B cell PRS (n=1248)
| OR* (95% CI) | P value | |
| ACR criteria23 | ||
| ACR 1: malar rash | 0.97 (0.74 to 1.26) | 0.81 |
| ACR 2: discoid rash | 0.77 (0.56 to 1.07) | 0.12 |
| ACR 3: photosensitivity | 0.93 (0.70 to 1.22) | 0.59 |
| ACR 4: oral ulcer | 0.94 (0.71 to 1.26) | 0.68 |
| ACR 5: arthritis | 0.99 (0.73 to 1.34) | 0.95 |
| ACR 6: serositis | 1.19 (0.91 to 1.56) | 0.21 |
| ACR 7: renal disorder | 1.20 (0.91 to 1.59) | 0.20 |
| ACR 8: neurological disorder | 1.16 (0.75 to 1.80) | 0.50 |
| ACR 9: haematological disorder | 1.05 (0.80 to 1.37) | 0.74 |
| ACR 10: immunological disorder | 1.44 (1.08 to 1.93) | 0.014 |
| ACR 11: ANA | 1.04 (0.38 to 2.87) | 0.94 |
| Antibodies | ||
| dsDNA | 1.47 (1.07 to 2.01) | 0.018 |
| Sm | 0.91 (0.57 to 1.46) | 0.71 |
| Cardiolipin*† | 1.01 (0.76 to 1.35) | 0.93 |
| Lupus anticoagulant | 1.08 (0.76 to 1.53) | 0.68 |
| β2-glycoprotein† | 1.20 (0.84 to 1.72) | 0.33 |
| SSA | 1.17 (0.89 to 1.53) | 0.26 |
| SSB | 1.09 (0.80 to 1.50) | 0.58 |
| Complement | ||
| Low C3/C4/CH50‡ | 1.21 (0.90 to 1.64) | 0.21 |
Values in bold indicate p<0.05.
*ORs for PRSs in the highest quartile compared with quartiles 1–3.
†IgM or IgG.
‡Low complement levels defined according to the SLICC-12 criteria.24
ACR, American College of Rheumatology; dsDNA, double-stranded DNA; PRS, polygenic risk score; SLICC, Systemic Lupus International Collaborating Clinics; SSA, Sjögren’s syndrome-related antigen A; SSB, Sjögren’s syndrome-related antigen B.